News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,149 Results
Type
Article (13760)
Company Profile (101)
Press Release (251288)
Section
Business (88037)
Career Advice (465)
Deals (15342)
Drug Delivery (67)
Drug Development (36600)
Employer Resources (49)
FDA (6288)
Job Trends (6196)
News (150201)
Policy (14027)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (440)
Adcomms (6)
Allergies (32)
Alliances (23211)
ALS (36)
Alzheimer's disease (386)
Antibody-drug conjugate (ADC) (36)
Approvals (6326)
Artificial intelligence (101)
Autoimmune disease (7)
Automation (3)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (55)
Biotechnology (40)
Bladder cancer (19)
Brain cancer (15)
Breast cancer (74)
Cancer (580)
Cardiovascular disease (70)
Career advice (407)
Career pathing (11)
CAR-T (20)
Cell therapy (83)
Cervical cancer (4)
Clinical research (30871)
Collaboration (323)
Compensation (134)
Complete response letters (17)
COVID-19 (757)
CRISPR (19)
C-suite (117)
Cystic fibrosis (35)
Data (598)
Denatured (15)
Depression (9)
Diabetes (77)
Diagnostics (1316)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (55)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32073)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37387)
Executive appointments (356)
FDA (6680)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (204)
Gene editing (37)
Generative AI (8)
Gene therapy (99)
GLP-1 (339)
Government (1286)
Grass and pollen (2)
Guidances (15)
Healthcare (3564)
Huntington's disease (4)
IgA nephropathy (10)
Immunology and inflammation (34)
Indications (12)
Infectious disease (789)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (45)
Interviews (59)
IPO (5874)
IRA (29)
Job creations (2050)
Job search strategy (373)
Kidney cancer (6)
Labor market (10)
Layoffs (177)
Leadership (3)
Legal (3429)
Liver cancer (19)
Lung cancer (78)
Lymphoma (52)
Machine learning (1)
Management (16)
Manufacturing (142)
MASH (31)
Medical device (1275)
Medtech (1277)
Mergers & acquisitions (9655)
Metabolic disorders (246)
Multiple sclerosis (19)
NASH (14)
Neurodegenerative disease (22)
Neuropsychiatric disorders (6)
Neuroscience (555)
NextGen: Class of 2025 (1587)
Non-profit (593)
Northern California (676)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (13)
Parkinson's disease (42)
Partnered (7)
Patents (104)
Patient recruitment (28)
Peanut (10)
People (28867)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8035)
Phase II (13059)
Phase III (11724)
Pipeline (406)
Podcasts (46)
Policy (58)
Postmarket research (1401)
Preclinical (3207)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (158)
Real estate (2633)
Recruiting (17)
Regulatory (10086)
Reports (14)
Research institute (564)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (7)
Schizophrenia (35)
Series A (35)
Series B (11)
Service/supplier (3)
Sickle cell disease (31)
Southern California (691)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1627)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (28)
United States (6840)
Vaccines (150)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (89)
Last 7 days (262)
Last 30 days (987)
Last 365 days (12100)
2025 (3008)
2024 (12501)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14886)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (54)
Arkansas (3)
Asia (20088)
Australia (2603)
California (1632)
Canada (872)
China (228)
Colorado (65)
Connecticut (65)
Delaware (53)
Europe (39351)
Florida (304)
Georgia (36)
Idaho (9)
Illinois (185)
India (14)
Indiana (128)
Iowa (1)
Japan (86)
Kansas (55)
Kentucky (12)
Maine (2)
Maryland (245)
Massachusetts (1407)
Michigan (28)
Minnesota (89)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (718)
New Mexico (7)
New York (475)
North Carolina (378)
North Dakota (2)
Northern California (676)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (412)
Puerto Rico (8)
Rhode Island (7)
South America (501)
South Carolina (2)
Southern California (691)
Tennessee (34)
Texas (218)
Utah (33)
Virginia (69)
Washington D.C. (29)
Washington State (111)
Wisconsin (14)
265,149 Results for "opiant pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.
Indivior PLC (LSE: INDV) (“Indivior” or the “Company”) today announced that it has completed the acquisition of Opiant Pharmaceuticals, Inc. (“Opiant”).
March 2, 2023
·
7 min read
Deals
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the previously announced Merger Agreement (the Agreement) for Opiant to be acquired by Indivior PLC (LSE: INDV).
February 7, 2023
·
9 min read
Deals
Indivior PLC to Acquire Opiant Pharmaceuticals
Opiant Pharmaceuticals Inc. announced that it has entered into a definitive merger agreement to be acquired by Indivior Inc, a subsidiary of Indivior PLC.
November 14, 2022
·
10 min read
Biotech Beach
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for OPNT003, nasal nalmefene, Opiant’s product candidate for the treatment of opioid overdose.
January 19, 2023
·
4 min read
Biotech Beach
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
Opiant Pharmaceuticals Inc. announced the expiration of the waiting period under the United States Hart-Scott-Rodino Act of 1976, as amended, with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC.
February 6, 2023
·
8 min read
Deals
Indivior To Acquire Opiant Pharmaceuticals
Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in cash, plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch.
November 14, 2022
·
15 min read
Business
Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reported financial results for the three months and nine months ended September 30, 2022.
November 14, 2022
·
11 min read
Deals
Indivior Bets $145M on Opiant’s Opioid Overdose Recovery Candidate
Indivior PLC announced it will acquire Opiant Pharmaceuticals and its lead candidate OPNT003, an intranasal-delivered opioid overdose recovery product.
November 14, 2022
·
3 min read
·
Alex Keown
Biotech Beach
Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has completed submission of its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for OPNT003, nasal nalmefene, for the treatment of opioid overdose.
November 22, 2022
·
3 min read
Business
Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended September 30, 2022, after the financial markets close on Monday, November 14, 2022.
October 27, 2022
·
1 min read
1 of 26,515
Next